Home › Multiple Myeloma › Indiana › Indianapolis
Multiple Myeloma clinical trials in Indianapolis, IN
13 studies for Multiple Myeloma are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Franciscan Health, Indianapolis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
- Indiana University, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Collection of Tissue Samples for Cancer Research
RecruitingObservational study
- Indiana University - Purdue, Indianapolis
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RecruitingPhase 1
- Indiana University, Indianapolis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- Indiana University Health, Indianapolis
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- Franciscan St. Francis Health /ID# 280928, Indianapolis
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RecruitingPhase 1
- Indiana University Health Simon Cancer Center, Indianapolis
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecruitingPhase 1/2
- Community Health Network, Indianapolis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Saint Catherine Hospital, Indianapolis
The Indiana Myeloma Registry
RecruitingObservational study
- Indiana University Simon Cancer Center, Indianapolis
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)24 studies
- Heart Failure23 studies
- Breast Cancer20 studies
- Obesity20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer18 studies
- Ovarian Cancer17 studies
- Lung Cancer16 studies
- Cardiovascular Disease16 studies
- Type 1 Diabetes14 studies
- Endometrial Cancer14 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.